Home
Translating Innovation to Success in Antimicrobial Drug Discovery and Development
15 March 2011
Translating Innovation to Success in Antimicrobial Drug Discovery and Development

Workshop hosts:

  • Dr. Nafsika Georgopapadakou,
    Anti-infective Research Consultant,
    Montreal - Canada
     
  • Dr. Bozena Korczak,
    Senior Vice President, Chief Development Officer,
    PolyMedix, Radnor - USA
     
  • Dr. Barry Eisenstein
    Senior VP, Scientific Affairs,
    Cubist Pharmaceuticals, Lexington - USA


Who should attend this workshop?

All those responsible for research, medical microbiology, antimicrobial therapeutics and clinical development, including:

  • Chief Scientific Officers
  • Senior Vice Presidents
  • Chief Medical Officers
  • Research Scientists
  • Clinical Microbiologists
  • R&D Project Managers
  • Heads of Anti-Infectives Discovery
  • Clinical Trials Managers
  • Principal Scientists
  • Senior Vice Presidents of R&D

Scroll down for the workshop timetable.

Register your place   View a Brochure  

What is this workshop about?

After briefly highlighting infectious disease areas of greatest medical need and commercial opportunity, the workshop will provide insights into the stages of the antimicrobial drug discovery process with the goal of increasing the probability of success. Critical issues for each stage - from target selection to IND-enabling studies - will be outlined, with examples from real cases of success/failure.  The impact and limitations of recent innovations - genomics, bioinformatics, high through screening, combinatorial chemistry - in drug discovery will be discussed.   Goal posts likely to lead to progression of an active compound to a drug will be defined, as well as minimal in-house resources and skills required for compounds to progress. 

There will be a number of case studies covered, including the interesting and eventually successful development of daptomycin for injection (Cubicin). This antibiotic had been developed through phase 2 at Eli Lilly in the 1980's, but was abandoned because of safety reasons. It was later licensed to Cubist Pharmaceuticals, a small start-up company, who were able to make a key discovery relating to appropriate dosing that enabled continued development. This antibiotic was subsequently successfully developed and approved for both complicated bacterial skin infection and for Staphylococcus aureus bacteremia, including with right-sided endocarditis, but failed in community acquired bacterial pneumonia for reasons that will also be discussed.

Workshop agenda

clock

12:10

Registration & Coffee

clock

12:15

Welcome & Introductions

clock

12:20

Antimicrobial target selection: Organisms, biochemical targets

Nafsika Georgopapadakou

Nafsika Georgopapadakou, , Anti-infective Research Consultant

clock

12:50

In-vitro and in-vivo testing

Nafsika Georgopapadakou

Nafsika Georgopapadakou, , Anti-infective Research Consultant

  • Mechanism of action
  • Cidal/static, post-antibiotic effect
  • Resistance: Frequency, fitness, cross-resistance
  • Effect of serum on antimicrobial activity
  • Mammalian cytotoxicity
  • clock

    13:20

    Animal studies

    Nafsika Georgopapadakou

    Nafsika Georgopapadakou, , Anti-infective Research Consultant

  • Toxicity:  Acute, mechanism-related
  • Pharmacokinetics
  • Efficacy in relevant infection models
  • Outsourcing testing in a cost-effective manner
  • clock

    13:50

    Operational and regulatory aspect of preparation for your First in Man study

    Bozena Korczak

    Bozena Korczak, Senior Vice President, Chief Development Officer, PolyMedix, Inc.

  • Drug substance and drug product
  • Pre-IND/CTA meeting
  • Design and objectives for phase 1
  • clock

    14:35

    Afternoon Coffee

    clock

    15:05

    Progression to phase 2 and beyond

    Bozena Korczak

    Bozena Korczak, Senior Vice President, Chief Development Officer, PolyMedix, Inc.

  • Activities behind the main scene
  • Do it yourself or outsource
  • clock

    15:50

    Case study: Development of daptomycin for injection

    Barry Eisenstein

    Barry Eisenstein, Senior VP, Scientific Affairs, Cubist Pharmaceuticals

  • History of daptomycin - from Lilly's abandonment to Cubist's success
  • The successful clinical development for both complicated bacterial skin infection and for Staphylococcus aureus bacteremia
  • The unsuccessful application for community acquired bacterial pneumonia indication
  • How can we take what we have learned and make immediate improvements in our development processes
  • clock

    16:30

    Discussion & questions / Review of the session

    Nafsika Georgopapadakou

    Nafsika Georgopapadakou, , Anti-infective Research Consultant

    Bozena Korczak

    Bozena Korczak, Senior Vice President, Chief Development Officer, PolyMedix, Inc.

    Barry Eisenstein

    Barry Eisenstein, Senior VP, Scientific Affairs, Cubist Pharmaceuticals

    clock

    17:00

    Close of Workshop

    Millennium Gloucester Hotel

    Harrington Gardens
    London SW7 4LH
    United Kingdom

    Millennium Gloucester Hotel


    Title

    SubTitle
    speaker image

    Content

    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download

    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group


    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.